Q-linea AB (publ) (OMX: QLINEA) today announces the signing of the first US commercial contract for ASTar® instrumentation.

ASTar will be installed in a not-for-profit healthcare system, installation is planned for January.

Jim Kathrein, VP of US Commercial Operations, stated, “We are thrilled with this progress and continued commercial traction. This healthcare system consists of over 50 hospitals, and we anticipate expansion within their network as clinical evidence of ASTar’s impact on patients with bacteremia is realized.”

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

First US customer signs commercial contract